| Literature DB >> 15785740 |
N M Wheelhouse1, P B S Lai, S J Wigmore, J A Ross, D J Harrison.
Abstract
The largest single underlying cause of hepatocellular carcinoma (HCC) worldwide is hepatitis B virus (HBV) infection. Hepatitis B virus increases cellular oxidative stress and the development of HCC occurs after a long latency period. The study was carried out to determine whether mitochondrial DNA abnormalities were associated with HCC in individuals with HBV. The frequency of mutation and deletion of specific areas of the mitochondrial genome in tumour and matched normal tissue of patients with HBV infection was investigated in the current study. The percentage of control subjects harbouring D-loop mutations was 11%, which was significantly lower than that observed in both the noncancerous (49%, P=0.033) and tumour tissue (59%, P=0.014) of patients with HCC. In contrast, the number of cases in which the common 4977 bp deletion of the mitochondrial genome was detected was significantly greater in control liver and noncancerous liver tissue of subjects with HCC (100 and 95%, respectively) than in cancerous liver tissue (28%, P<0.001). These observations suggest that the inflammatory process contributes to the rate of mitochondrial mutations. However, the lower frequency of the large deletion in cancerous tissue suggests that there is selection against either mitochondria, which harbour large deletions, or against cells that contain these mitochondria during hepatocarcinogenesis.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15785740 PMCID: PMC2361973 DOI: 10.1038/sj.bjc.6602496
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of patients with HCC and their tumours
|
|
| |
|---|---|---|
| Age (years) | 55 (32–78) | |
|
| ||
| Male | 55 | (89%) |
| HBV | 58 | (94%) |
| HCV | 5 | (8%) |
|
| ||
| Normal | 6 | (10%) |
| Fibrosis | 19 | (31%) |
| Cirrhosis | 37 | (60%) |
|
| ||
| 1 | 2 | (3%) |
| 2 | 39 | (63%) |
| 3 | 15 | (24%) |
| 4 | 6 | (10%) |
| Tumour maximum size (cm) | 3.5 (1.6–11.9) | |
|
| ||
| Y | 34 | (50%) |
| N | 18 | (29%) |
| No capsule | 10 | (21%) |
|
| ||
| Y | 8 | (13%) |
| N | 54 | (87%) |
| Serum alpha fetoprotein (U/l) | 96 (2–699 800) | |
HCC=hepatocellular carcinoma; HBV=hepatitis B virus; HCV=hepatitis B virus.
Figure 1Frequency of mutation in the D-loop region of (A) control tissue, (B) noncancerous liver tissue and (C) HCC tumour tissue. (D) shows a typical gel. M: markers. Lane C shows the negative control. Lanes 1, 2 and 3 show PCR products derived from control, noncancerous and tumour liver tissue, respectively.
Figure 2(A) Frequency of the 4977 bp deletion in control tissue, noncancerous tissue and HCC liver tissue. (B) A typical gel. Lanes Ci and Co are the negative control lanes for MITIN and MITOUT PCRs. Lanes 1 and 3 show the 142 bp PCR products derived from using the MITIN internal control primers. Lanes 2 and 4 show the presence and absence of the deleted band, respectively (214 bp).